Humana Inc.
HUMHIGH VELOCITYFILING INTENSITYHumana Inc. reads as an High Velocity (composite 78/100); Consistent Strategic Buyer deploying $403M across 0 disclosed transactions, down 92% vs the prior cycle · primary market Healthcare.
Lens
Disclosed M&A capital (2023–2025)
$403M
vs $5.2B in 2020–2022
Disclosed transactions
N/A
3/3 active fiscal years in window
Buyer archetype
Consistent Strategic Buyer
Meaningful spend appears across repeat years.
Composite score
78
High Velocity dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $9.4B disclosed buyer spend
- Filed within 27d
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 27d
- 18 acquisition-history signals
- 462 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- 4 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 4 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 4 activism filings
- Latest activism 23y ago; heavily discounted
Distress Watch
Issuers showing financial-distress filing patterns
- 4 activism filings
Restatement Risk
Issuers with accounting-integrity flags from filings
Capital Velocity
DominantIssuers with the highest filing-activity intensity
- 462 8-Ks
- Filed within 27d
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $42.1B
- 10-Q 27d ago
- 2 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $4,187M · Peak count: 2
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | N/A | $81M | N/A | N/A |
| 2024 | N/A | $89M | N/A | N/A |
| 2023 | N/A | $233M | N/A | N/A |
| 2022 | N/A | $337M | N/A | N/A |
| 2021 | N/A | $4.2B | N/A | N/A |
| 2020 | 1 | $709M | $709M | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Geographic Expansion25%
- Bolt On25%
- Platform25%
- Horizontal Consolidation25%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- geographic_expansion
- horizontal_consolidation
- bolt_on
- platform
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“We believe that barriers to entry in our markets are not substantial, so the addition of new competitors can occur relatively easily, and customers enjoy significant flexibility in moving between competitors through the Medicare Annual Enrollment Period.”
“We are in a highly competitive industry. Some of our competitors are more established in the health care industry in terms of a larger market share and have greater financial resources than we do in some markets.”
“Fully integrating KAH's home health operations into our Home solutions business will allow us to accelerate clinical innovation and roll out a value-based operating model at scale.”
“In addition to the challenge of controlling health care costs, we face intense competitive pressure to contain premium prices.”
“The KAH acquisition reflects our continued commitment to investing in home-based clinical solutions.”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Healthcare
- Market spend (2023–2025)
- $195B
- Market spend (2020–2022)
- $253.6B
- Recent vs prior
- −23%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
HUM trades at a +1.0-turn premium to the Healthcare peer median of 13.7×.
- EV / Revenue
- 0.3×
- Net debt / EBITDA
- 2.6×
- Peer median EV / EBITDA
- 13.7×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
| 17.2× | 0.9× | 1.9× | $449.7B | $28.1B | |
| 16.6× | 0.5× | 4.6× | $407.9B | $17.1B | |
Humana Inc.HUM | 14.8× | 0.3× | 2.6× | $137.2B | $403M |
| 13.7× | 0.2× | 0.4× | $403.4B | $1.2B | |
| 11.7× | 0.5× | 2.5× | $200.4B | $6.4B | |
| 9.3× | 1.9× | 2.8× | $76.4B | $1.3B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Healthcare. Bars scaled to the highest EV/EBITDA in the set.
Target landscape.
Public-issuer targets that fit this buyer's archetype and target categories from filing-derived signal. Scores reflect cross-signal fit; reasons cite the EDGAR-anchored facts that drove the match.
No qualifying public-issuer targets surfaced from the current signal mix.
Stated target categories
No target categories enumerated in the audited corpus for this issuer.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)312026-02-19
- 10-Q (quarterly)992026-04-29
- 8-K (event)4622026-04-29
- Proxy / DEF 14A642026-03-06
- Activism (13D / DFAN / PREC)42003-11-12
Signals on file
- elevated
Activism on file
2003-11-124 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Disclosed acquisition spend
- info
Signal
10-K strategy themes
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.